Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary nitroprusside versus adenosine for FFR measurement in moderate coronary stenosis
IRCT20251005067509N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sodium nitroprusside and adenosine in coronary arteriosclerosis, sponsored by Tehran University of Medical Sciences. Primary endpoints: Fractional flow reserve after adenosine and nitroprusside and Non-inferiority of nitroprusside-induced maximal hyperemia versus adenosine. Started Nov 2025; status: completed.
02
Drugs
sodium nitroprussideadenosine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20251005067509N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251005067509N1.